| Literature DB >> 27939618 |
Giovanna Poce1, Sara Consalvi2, Martina Cocozza2, Raquel Fernandez-Menendez3, Robert H Bates3, Fátima Ortega Muro3, David Barros Aguirre3, Lluis Ballell3, Mariangela Biava2.
Abstract
BM635 is a small molecule endowed with outstanding anti-mycobacterial activity (minimum inhibitory concentration of 0.12μM against M. tuberculosis H37Rv) identified during a hit-to-lead campaign. Its poor aqueous solubility together with its high lipophilicity led to low exposure in vivo. Indeed, the half-life in vivo of BM635 was 1h, allowing a reasonable maximum concentration (Cmax=1.62μM) and a moderate bioavailability (46%). The present study aimed to develop salt forms of BM635 with pharmaceutically accepted hydrochloric, methanesulphonic, phosphoric, tartaric, and citric acids to overcome these drawbacks. BM635 salts (BM635-HCl, BM635-Mes, BM635-PA, BM635-TA and BM635-CA) were evaluated for physicochemical as well as biopharmaceutical attributes.Entities:
Keywords: BM635; Drug development; MmpL3; Pharmaceutical salts; Tuberculosis
Mesh:
Substances:
Year: 2016 PMID: 27939618 DOI: 10.1016/j.ejps.2016.12.003
Source DB: PubMed Journal: Eur J Pharm Sci ISSN: 0928-0987 Impact factor: 4.384